Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir disproxil

- PMLiVE

Novo Nordisk appoints Liz Skrbkova

She moves from the pharma company's UK operations for a new role in Denmark

- PMLiVE

Heart drug sales continue downward spiral

But revenue has stabilised after a tough three years of patent expiries

- PMLiVE

Schultz takes Lundbeck helm after leaving Novo Nordisk

Former executive left Danish firm just days ago

- PMLiVE

Prescribing costs jump in England

New report finds that asthma and diabetes drugs the most costly to the NHS

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

- PMLiVE

Takeda to pay $2.4bn to settle Actos cancer suits

Will be one of the largest drug safety settlements in US history

- PMLiVE

Relief as study finds no cardiovascular risk with Januvia

FDA continues to investigate safety of numerous diabetes therapies

- PMLiVE

Sanofi wins European approval for Lantus follow-up Toujeo

Long-acting insulin is a key part of the company's growth plans

Sanofi reception

Sanofi gains accelerated review for rare disease drug

New pill for Fabry disease could be approved by the FDA before the end of the year

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo backed as melanoma therapy in EU

First checkpoint inhibitor to be recommended for approval in the region

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

- PMLiVE

Saxenda debuts in US with $1,000-a-month price tag

It is the first market for Novo Nordisk’s obesity therapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links